4t1 luc murine breast cancer Search Results


90
SibTech Inc 4t1- luc murine breast cancer
(A-D) 12-week old female BALB/c mice were grafted with breast cancer <t>(4T1)</t> cells and subject to (A) multiple cycles of FMD or STS alone or to (C, D) a combination of FMD and the chemotherapy drugs (C) doxorubicin (DXR) or (D) cyclophosphamide (CP). (B) Circulating IGF-1 levels at the end of STS or FMD in (A) were measured. (E) 12-week old female C57BL/6 mice were grafted with melanoma (B16) cells and subject to multiple cycles of FMD alone or in combination with DXR. Tumor volume at multiple time-points (on the left) and immediately prior to euthanasia (on the right) are reported for each set of treatments. The animals receiving chemotherapy were injected at the end of each FMD cycle (shaded area). [(A, B) n=10, (C) n=13, (D) n=10, and (E) n=15]. Data represented as mean ± SEM. One-way ANOVA (Tukey post-analysis test) was performed. p-values <0.05, 0.01 and 0.001 are indicated as *, **, and ***, respectively. See also Figure S1.
4t1 Luc Murine Breast Cancer, supplied by SibTech Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/4t1- luc murine breast cancer/product/SibTech Inc
Average 90 stars, based on 1 article reviews
4t1- luc murine breast cancer - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


(A-D) 12-week old female BALB/c mice were grafted with breast cancer (4T1) cells and subject to (A) multiple cycles of FMD or STS alone or to (C, D) a combination of FMD and the chemotherapy drugs (C) doxorubicin (DXR) or (D) cyclophosphamide (CP). (B) Circulating IGF-1 levels at the end of STS or FMD in (A) were measured. (E) 12-week old female C57BL/6 mice were grafted with melanoma (B16) cells and subject to multiple cycles of FMD alone or in combination with DXR. Tumor volume at multiple time-points (on the left) and immediately prior to euthanasia (on the right) are reported for each set of treatments. The animals receiving chemotherapy were injected at the end of each FMD cycle (shaded area). [(A, B) n=10, (C) n=13, (D) n=10, and (E) n=15]. Data represented as mean ± SEM. One-way ANOVA (Tukey post-analysis test) was performed. p-values <0.05, 0.01 and 0.001 are indicated as *, **, and ***, respectively. See also Figure S1.

Journal: Cancer cell

Article Title: Fasting mimicking diet reduces HO-1 to promote T cell-mediated tumor cytotoxicity

doi: 10.1016/j.ccell.2016.06.005

Figure Lengend Snippet: (A-D) 12-week old female BALB/c mice were grafted with breast cancer (4T1) cells and subject to (A) multiple cycles of FMD or STS alone or to (C, D) a combination of FMD and the chemotherapy drugs (C) doxorubicin (DXR) or (D) cyclophosphamide (CP). (B) Circulating IGF-1 levels at the end of STS or FMD in (A) were measured. (E) 12-week old female C57BL/6 mice were grafted with melanoma (B16) cells and subject to multiple cycles of FMD alone or in combination with DXR. Tumor volume at multiple time-points (on the left) and immediately prior to euthanasia (on the right) are reported for each set of treatments. The animals receiving chemotherapy were injected at the end of each FMD cycle (shaded area). [(A, B) n=10, (C) n=13, (D) n=10, and (E) n=15]. Data represented as mean ± SEM. One-way ANOVA (Tukey post-analysis test) was performed. p-values <0.05, 0.01 and 0.001 are indicated as *, **, and ***, respectively. See also Figure S1.

Article Snippet: Cancer cell lines and tumor cell injection MCF7 human breast adenocarcinoma (gift from Amy Lee – University of Southern California), 4T1- luc murine breast cancer (SibTech, Inc.) and B16 murine melanoma (gift from Noah Craft, UCLA) cell lines were cultured in high glucose (4.5g/L) Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS (Thermo Fisher Scientific Inc.) at 37°C and 5% CO 2 .

Techniques: Injection

(A) Bone marrow collected from BALB/c mice undergoing FMD/DXR treatments (see Figure S3A) was collected at the end of the experiment and analyzed with FACS (n=6) to assess the amount of Common Lymphoid Progenitors (CLP). (B) Breast cancer (4T1) tumor tissues collected at the end of the experiment (see Figure S3A) were analyzed using immunohistochemistry to assess CD3+/CD8+ TILs (n=8) (quantification on the right). (C, E) CD3+/CD8+ and (D, E) CD3+/CD4+/CD25+were also assessed by FACS analysis (n=7) in tumor tissue collected from a separate, equivalent experiment (see Figure 1C). (F) Melanoma (B16) tissue collected (see Figure 1E) was also processed to assess the levels of TILs (quantification on the right). Bar scale for DAPI, CD3 and CD8 is 75 μm. Bar scale for CD3+/CD8+ is 12.5 μm Data represented as mean ± SEM. The significance of the differences between experimental groups was determined by using one-way ANOVA (Tukey post-analysis test). p-values <0.05, 0.01 and 0.001 are indicated as *, **, and ***, respectively. See also Figure S2.

Journal: Cancer cell

Article Title: Fasting mimicking diet reduces HO-1 to promote T cell-mediated tumor cytotoxicity

doi: 10.1016/j.ccell.2016.06.005

Figure Lengend Snippet: (A) Bone marrow collected from BALB/c mice undergoing FMD/DXR treatments (see Figure S3A) was collected at the end of the experiment and analyzed with FACS (n=6) to assess the amount of Common Lymphoid Progenitors (CLP). (B) Breast cancer (4T1) tumor tissues collected at the end of the experiment (see Figure S3A) were analyzed using immunohistochemistry to assess CD3+/CD8+ TILs (n=8) (quantification on the right). (C, E) CD3+/CD8+ and (D, E) CD3+/CD4+/CD25+were also assessed by FACS analysis (n=7) in tumor tissue collected from a separate, equivalent experiment (see Figure 1C). (F) Melanoma (B16) tissue collected (see Figure 1E) was also processed to assess the levels of TILs (quantification on the right). Bar scale for DAPI, CD3 and CD8 is 75 μm. Bar scale for CD3+/CD8+ is 12.5 μm Data represented as mean ± SEM. The significance of the differences between experimental groups was determined by using one-way ANOVA (Tukey post-analysis test). p-values <0.05, 0.01 and 0.001 are indicated as *, **, and ***, respectively. See also Figure S2.

Article Snippet: Cancer cell lines and tumor cell injection MCF7 human breast adenocarcinoma (gift from Amy Lee – University of Southern California), 4T1- luc murine breast cancer (SibTech, Inc.) and B16 murine melanoma (gift from Noah Craft, UCLA) cell lines were cultured in high glucose (4.5g/L) Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS (Thermo Fisher Scientific Inc.) at 37°C and 5% CO 2 .

Techniques: Immunohistochemistry

(A) The effect of FMD on breast tumor growth (4T1) in immunodeficient BALB/c nude mice (n=15) (see Figure S4A-E); (B) The survival of wild type (WT) and nude mice injected with high dose of DXR and undergoing ad lib or FMD regimen. (C-H) 4T1 breast tumor-bearing mice were treated with DXR, FMD+DXR alone or in combination with [.alpha]CD8 monoclonal antibody and (C-E) circulating levels of (C, E) CD3+/CD8+ and (D, E) CD3+/CD4+/CD25+ were determined by FACS (n=7). (F) Tumor volumes of FMD+DXR and FMD+DXR+αCD8 were measured at multiple time points, and (G) TILs were also assessed in tumor samples collected from the same animals. (H) Circulating lymphocytes from DXR, FMD+DXR, DXR+αCD8, and FMD+DXR+αCD8 these animals were collected and cultured ex vivo with 4T1 cells for 24 hours and viability was assessed by MTT reduction. (I) Mice were immunized by subcutaneous inoculation (in the left flank) with 4T1 breast cancer cells preconditioned in vitro with either ad lib- (2 g/L glucose+10% FBS) or STS-medium (0.5 g/L glucose+1% FBS) with or without doxorubicin (5 μM). 7 days after the immunization, the same animals were inoculated with naïve 4T1 cells in the right flank (n=10). (J, K) Tumor progression for the immunization (left) and the naïve (right) sides are reported. Data represented as mean ± SEM. One-way ANOVA (Tukey post-analysis test) and Log-rank (Mantel-Cox) test (survival) was performed. Comparisons between groups were performed with Student's t test. p-values <0.05, 0.01 and 0.001 are indicated as *, **, and ***, respectively. See also Figure S3.

Journal: Cancer cell

Article Title: Fasting mimicking diet reduces HO-1 to promote T cell-mediated tumor cytotoxicity

doi: 10.1016/j.ccell.2016.06.005

Figure Lengend Snippet: (A) The effect of FMD on breast tumor growth (4T1) in immunodeficient BALB/c nude mice (n=15) (see Figure S4A-E); (B) The survival of wild type (WT) and nude mice injected with high dose of DXR and undergoing ad lib or FMD regimen. (C-H) 4T1 breast tumor-bearing mice were treated with DXR, FMD+DXR alone or in combination with [.alpha]CD8 monoclonal antibody and (C-E) circulating levels of (C, E) CD3+/CD8+ and (D, E) CD3+/CD4+/CD25+ were determined by FACS (n=7). (F) Tumor volumes of FMD+DXR and FMD+DXR+αCD8 were measured at multiple time points, and (G) TILs were also assessed in tumor samples collected from the same animals. (H) Circulating lymphocytes from DXR, FMD+DXR, DXR+αCD8, and FMD+DXR+αCD8 these animals were collected and cultured ex vivo with 4T1 cells for 24 hours and viability was assessed by MTT reduction. (I) Mice were immunized by subcutaneous inoculation (in the left flank) with 4T1 breast cancer cells preconditioned in vitro with either ad lib- (2 g/L glucose+10% FBS) or STS-medium (0.5 g/L glucose+1% FBS) with or without doxorubicin (5 μM). 7 days after the immunization, the same animals were inoculated with naïve 4T1 cells in the right flank (n=10). (J, K) Tumor progression for the immunization (left) and the naïve (right) sides are reported. Data represented as mean ± SEM. One-way ANOVA (Tukey post-analysis test) and Log-rank (Mantel-Cox) test (survival) was performed. Comparisons between groups were performed with Student's t test. p-values <0.05, 0.01 and 0.001 are indicated as *, **, and ***, respectively. See also Figure S3.

Article Snippet: Cancer cell lines and tumor cell injection MCF7 human breast adenocarcinoma (gift from Amy Lee – University of Southern California), 4T1- luc murine breast cancer (SibTech, Inc.) and B16 murine melanoma (gift from Noah Craft, UCLA) cell lines were cultured in high glucose (4.5g/L) Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS (Thermo Fisher Scientific Inc.) at 37°C and 5% CO 2 .

Techniques: Injection, Cell Culture, Ex Vivo, In Vitro

(A) HO-1 expression levels of grafted 4T1 tumor and normal (liver and skeletal muscle) tissues collected from ad lib fed and mice undergoing STS or FMD regimen were analyzed with qRT-PCR. (B) HO-1 levels in 4T1 cells following 48 hours of in vitro STS were measured by Western blotting (n=3) (Blot was captured with Bio-Rad ChemiDoc, and unedited, representative bands are shown. (C, E, G) Viability of 4T1 cells was determined by MTT reduction following (C) DXR and hemin (10 M), (E) CP and hemin (10 M), and (G) CP and ZnPP (20 M). (D, F) Viability of 4T1 cell stably over-expressing HO-1 (pHO-1) or empty vector (pEV) was determined by MTT following (D) DXR and (F) CP under control and STS conditions. Data represented as mean ± SEM. The significance of the differences between experimental groups was determined by using one-way ANOVA (Tukey post-analysis test). Comparisons between groups were performed with Student's t test. p-values <0.05, 0.01 and 0.001 are indicated as *, **, and ***, respectively. See also Figure S5.

Journal: Cancer cell

Article Title: Fasting mimicking diet reduces HO-1 to promote T cell-mediated tumor cytotoxicity

doi: 10.1016/j.ccell.2016.06.005

Figure Lengend Snippet: (A) HO-1 expression levels of grafted 4T1 tumor and normal (liver and skeletal muscle) tissues collected from ad lib fed and mice undergoing STS or FMD regimen were analyzed with qRT-PCR. (B) HO-1 levels in 4T1 cells following 48 hours of in vitro STS were measured by Western blotting (n=3) (Blot was captured with Bio-Rad ChemiDoc, and unedited, representative bands are shown. (C, E, G) Viability of 4T1 cells was determined by MTT reduction following (C) DXR and hemin (10 M), (E) CP and hemin (10 M), and (G) CP and ZnPP (20 M). (D, F) Viability of 4T1 cell stably over-expressing HO-1 (pHO-1) or empty vector (pEV) was determined by MTT following (D) DXR and (F) CP under control and STS conditions. Data represented as mean ± SEM. The significance of the differences between experimental groups was determined by using one-way ANOVA (Tukey post-analysis test). Comparisons between groups were performed with Student's t test. p-values <0.05, 0.01 and 0.001 are indicated as *, **, and ***, respectively. See also Figure S5.

Article Snippet: Cancer cell lines and tumor cell injection MCF7 human breast adenocarcinoma (gift from Amy Lee – University of Southern California), 4T1- luc murine breast cancer (SibTech, Inc.) and B16 murine melanoma (gift from Noah Craft, UCLA) cell lines were cultured in high glucose (4.5g/L) Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS (Thermo Fisher Scientific Inc.) at 37°C and 5% CO 2 .

Techniques: Expressing, Quantitative RT-PCR, In Vitro, Western Blot, Stable Transfection, Plasmid Preparation, Control

(A-C) 4T1 tumor-bearing mice were treated with (A) ZnPP (40 mg/kg/day; IP; n=7), (B) STS and hemin (30 mg/kg/day; IP; n=7), and (C) FMD and hemin and DXR. (D) Mice bearing 4T1 tumors stably over-expressing HO-1 (pHO-1), or empty vector (pEV) were treated with DXR under ad lib or FMD regimens (n=10-15) (see Figure 1C). Data represented as mean ± SEM. One-way ANOVA (Tukey post-analysis test) was performed. p-values <0.05, 0.01 and 0.001 are indicated as *, **, and ***, respectively. See also Figure S6.

Journal: Cancer cell

Article Title: Fasting mimicking diet reduces HO-1 to promote T cell-mediated tumor cytotoxicity

doi: 10.1016/j.ccell.2016.06.005

Figure Lengend Snippet: (A-C) 4T1 tumor-bearing mice were treated with (A) ZnPP (40 mg/kg/day; IP; n=7), (B) STS and hemin (30 mg/kg/day; IP; n=7), and (C) FMD and hemin and DXR. (D) Mice bearing 4T1 tumors stably over-expressing HO-1 (pHO-1), or empty vector (pEV) were treated with DXR under ad lib or FMD regimens (n=10-15) (see Figure 1C). Data represented as mean ± SEM. One-way ANOVA (Tukey post-analysis test) was performed. p-values <0.05, 0.01 and 0.001 are indicated as *, **, and ***, respectively. See also Figure S6.

Article Snippet: Cancer cell lines and tumor cell injection MCF7 human breast adenocarcinoma (gift from Amy Lee – University of Southern California), 4T1- luc murine breast cancer (SibTech, Inc.) and B16 murine melanoma (gift from Noah Craft, UCLA) cell lines were cultured in high glucose (4.5g/L) Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS (Thermo Fisher Scientific Inc.) at 37°C and 5% CO 2 .

Techniques: Stable Transfection, Expressing, Plasmid Preparation

Mice bearing 4T1 or 4T1-pHO-1 breast tumors under FMD were treated with DXR and either hemin (30 mg/kg/day; IP) or CD8+ specific neutralizing monoclonal antibodies (αCD8; clone YTS 169.4) (n=13-15) (see Figures 3F and ​and5D).5D). (A) Tumor volumes were measured at multiple time-points (left) and immediately prior to euthanasia (right). (B-D) CD3+/CD8+ (CTL) and CD3+/CD4+/CD25+ (Treg)lymphocytes from the tumor bed was analyzed by FACS. Data represented as mean ± SEM. One-way ANOVA (Tukey post-analysis test) was performed. p-values <0.05, 0.01 and 0.001 are indicated as *, **, and ***, respectively.

Journal: Cancer cell

Article Title: Fasting mimicking diet reduces HO-1 to promote T cell-mediated tumor cytotoxicity

doi: 10.1016/j.ccell.2016.06.005

Figure Lengend Snippet: Mice bearing 4T1 or 4T1-pHO-1 breast tumors under FMD were treated with DXR and either hemin (30 mg/kg/day; IP) or CD8+ specific neutralizing monoclonal antibodies (αCD8; clone YTS 169.4) (n=13-15) (see Figures 3F and ​and5D).5D). (A) Tumor volumes were measured at multiple time-points (left) and immediately prior to euthanasia (right). (B-D) CD3+/CD8+ (CTL) and CD3+/CD4+/CD25+ (Treg)lymphocytes from the tumor bed was analyzed by FACS. Data represented as mean ± SEM. One-way ANOVA (Tukey post-analysis test) was performed. p-values <0.05, 0.01 and 0.001 are indicated as *, **, and ***, respectively.

Article Snippet: Cancer cell lines and tumor cell injection MCF7 human breast adenocarcinoma (gift from Amy Lee – University of Southern California), 4T1- luc murine breast cancer (SibTech, Inc.) and B16 murine melanoma (gift from Noah Craft, UCLA) cell lines were cultured in high glucose (4.5g/L) Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS (Thermo Fisher Scientific Inc.) at 37°C and 5% CO 2 .

Techniques: Bioprocessing